Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s price target on Insulet to $390 from $412 with a Buy rating on the shares. This sentiment was posted as part of the firm’s broader research note that previewed 2026 for MedTech. Truist expressed a more positive outlook on the healthcare sector for 2026 due to increasingly attractive relative valuations. However, the firm cautioned that the sector might act as a source of funds rather than a primary destination for new capital. Consequently, Truist advised investors to prioritize companies with specific 2026 catalysts.

A day prior, on December 17, Canaccord raised the firm’s price target on Insulet to $450 from $432 with a Buy rating on the shares. This was announced as Canaccord reaffirmed its bullish stance on the MedTech sector for 2026. The firm’s positive outlook is built on several key pillars: consistent demand from an aging demographic, a heightened focus on acute healthcare requirements, a robust M&A environment, and a market increasingly open to new IPOs. The firm particularly highlighted Insulet as a top pick and asserted that the company is primed for a multi-year cycle of outperformance due to the recent label expansion and the commercial rollout of Automated Insulin Delivery systems to the Type 2 diabetes patient population.

Earlier on December 16, Evercore ISI initiated coverage of Insulet with an Outperform rating and $370 price target. Despite the arrival of new competitors, the firm believes that Insulet’s unique tubeless design is effectively revolutionizing the insulin pump market and fueling substantial growth.

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the US and internationally.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.